Published in Oncology on January 01, 1991
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J (2010) 2.08
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (1999) 1.74
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J (2011) 1.74
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol (2004) 1.71
[Early diagnosis of breast cancer]. Med Clin (Barc) (1992) 1.70
Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A (2000) 1.69
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology (1998) 1.69
Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol (1989) 1.68
BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) Ann Oncol (1999) 1.62
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol (1999) 1.58
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol (2006) 1.58
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol (2005) 1.51
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J (2009) 1.51
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer (2012) 1.48
The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. Eur J Surg Oncol (2004) 1.44
[Experience with 150 subcutaneous venous reservoirs for venous access and infusion for the treatment of adult patients with oncologic and hematologic disorders and acquired immunodeficiency syndrome]. Med Clin (Barc) (1992) 1.40
Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol (2009) 1.40
[Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung]. Med Clin (Barc) (1997) 1.39
Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res (2001) 1.34
Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol (2000) 1.34
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res (2000) 1.30
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat (2009) 1.25
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat (2012) 1.22
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol (2005) 1.21
Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol (2000) 1.21
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer (2008) 1.19
Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol (1999) 1.17
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost (1996) 1.17
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene (1993) 1.14
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer (2008) 1.12
Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat (2005) 1.12
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol (2003) 1.11
Massive tumor implantation in the endoscopic resected area in modified nephroureterectomy. J Urol (1997) 1.08
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol (2010) 1.07
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer (2008) 1.06
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol (2004) 1.06
Lung cancer and cigarette smoking in women: a case-control study in Barcelona (Spain). Int J Cancer (1994) 1.05
Lack of transmission of porcine circovirus type 2 to weanling pigs by feeding them spray-dried porcine plasma. Vet Rec (2008) 1.04
Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther (2008) 1.04
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.02
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol (2014) 1.01
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol (2011) 1.01
Porcine epidemic abortion and respiratory syndrome (mystery swine disease). Isolation in Spain of the causative agent and experimental reproduction of the disease. Vet Microbiol (1992) 1.01
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer (2011) 1.01
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol (2000) 0.99
Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis (2001) 0.97
Molecular epidemiology of a large classical swine fever epidemic in the European Union in 1997-1998. Vet Microbiol (2000) 0.96
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer (2012) 0.95
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol (2002) 0.95
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol (2003) 0.94
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs (2013) 0.94
Local recurrence of low rectal cancer after abdominoperineal and anterior resection. Br J Surg (1997) 0.93
Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol (1998) 0.93
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol (2010) 0.92
Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet Microbiol (2009) 0.92
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer (1992) 0.92
Prospective study of microscopic lymph node involvement of the hepatic pedicle during curative hepatectomy for colorectal metastases. Br J Surg (1996) 0.91
K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer (1994) 0.90
Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum (2001) 0.90
Liver retransplantation for alcoholic cirrhosis recurring within a 21-month period. Transpl Int (1996) 0.89
Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst (2003) 0.89
Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol (1995) 0.87
Drug resistance in non-small cell lung cancer. Lung Cancer (2001) 0.87
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol (2000) 0.87
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol (2012) 0.86
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer (2000) 0.85
Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma. Carcinogenesis (2012) 0.85
Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J Hepatol (1997) 0.84
Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst (1997) 0.84
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene (1997) 0.84
Anti-Ri-associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer. Neurology (1993) 0.84
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Ann Oncol (2013) 0.83
Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study. Eur Arch Otorhinolaryngol (2013) 0.83
Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer. Br J Cancer (1997) 0.83
Systemic mastocytosis: a case report. Cytological, cytochemical and ultrastructural considerations. Acta Haematol (1977) 0.83
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol (2003) 0.82
Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Res Treat (2001) 0.82
Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res (1996) 0.82